News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Oct 26, 2020

Summary Toggle aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

Top line results are expected in the fourth quarter of 202 0 . Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment . SAN DIEGO , Oct. 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and
Oct 7, 2020

Summary Toggle aTyr Pharma to Participate in October Virtual Investor Events

SAN DIEGO , Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor events in
Sep 15, 2020

Summary Toggle aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers SAN DIEGO , Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Sep 14, 2020

Summary Toggle aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Sep 9, 2020

Summary Toggle aTyr Pharma to Present at September Investor Conferences

SAN DIEGO , Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September.
Sep 2, 2020

Summary Toggle aTyr Pharma to Present at Life Sciences Investor Forum on September 17th
Aug 13, 2020

Summary Toggle aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
Aug 11, 2020

Summary Toggle aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. SAN DIEGO , Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Aug 6, 2020

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
Jun 22, 2020

Summary Toggle aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO , June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.